Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061312 | 1.00 | PREP (0.44) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL197689 | 1.00 | PREP (0.44) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL29484188 | 0.95 | CTSK (0.46) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL2580872 | 0.93 | PREP (0.39) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL721602 | 0.90 | PREP (0.38) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL31587441 | 0.89 | CTSK (0.45) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL11803999 | 0.87 | CTSK (0.38) | PREPCTSKCTSSCTSLCTSB | |
| SCHEMBL4969025 | 0.87 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA2 | |
| SCHEMBL5696168 | 0.87 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA2 | |
| SCHEMBL23771884 | 0.86 | CTSK (0.38) | PREPCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113502230-B | Hericium erinaceus strain and culture method thereof, hericium erinaceus-ginseng bidirectional solid fermentation method and method for efficiently converting rare ginsenoside | 长春中医药大学 | 2023-07-04 | — | — | CN | claimed |
| US-11541091-B2 | Panax plant extract and pharmaceutical composition and use thereof | SHANGHAI HUIYU BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-01-03 | — | — | US | claimed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-12102721-B2 | Dosage forms of controlled release at specific gastrointestinal sites | Triastek, Inc. (CN) | 2024-10-01 | — | — | US | disclosed |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | Triastek, Inc. (CN) | 2024-07-23 | — | — | US | disclosed |
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | Oxford Drug Design Limited (GB) | 2023-10-31 | — | — | US | disclosed |
| EP-1372692-A4 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INST CANCER (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6887887-B2 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-05-03 | — | — | US | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | disclosed |
| EP-1372692-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | Sloan Kettering Institute For Cancer Research (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
| WO-2002074050-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, ACTR3 | PREP 2103/4885CTSK 1424/4885CTSS 488/4885 |
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | AARS1, NSUN3, GARS1 | PREP 873/4885CTSK 3008/4885CTSS 531/4885 |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | PREP 3079/4885CTSK 1788/4885CTSS 1556/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | PREP 1266/4885CTSK 1191/4885CTSS 929/4885 |
| US-11541091-B2 | Panax plant extract and pharmaceutical composition and use thereof | RXFP3, PCSK9, RXFP1 | PREP 3400/4885CTSK 3625/4885CTSS 3420/4885 |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | CYP3A43, HTR3D, CYP3A7 | PREP 3176/4885CTSK 2116/4885CTSS 2065/4885 |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, CYTH3 | PREP 2043/4885CTSK 1319/4885CTSS 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.